Ascendis Pharma News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

04.11.24	Ascendis Pharma and Novo Nordisk Sign Collaboration for Development and Commercialization of TransCon Technology-based Products in Metabolic and Cardiovascular Diseases (GlobeNewswire)
20.09.24	Ascendis Pharma Prices Public Offering Of 2 Mln ADSs At $150.00/ADS (RTTNews)
19.09.24	Ascendis Pharma Commences Underwritten Public Offering Of $300 Mln Of ADSs (RTTNews)
16.09.24	Ascendis Pivotal ApproaCH Study Of TransCon CNP In Achondroplasia Meets Primary Goal; Stock Up (RTTNews)
12.09.24	Ascendis Pharma Gets U.S. Orphan Drug Exclusivity For YORVIPATH In Adult Hypoparathyroidism (RTTNews)
04.09.24	Ascendis Pharma Reaches $150 Mln Royalty Funding Agreement With Royalty Pharma; Stock Drops (RTTNews)
18.08.24	Biotech Buzz: VIRX Cuts 23% Jobs, FDA Oks New Drug For Hypoparathyroidism, SIGA Down But Not Out (RTTNews)
12.08.24	Ascendis Rises In Pre-market On FDA Approval Of Yorvipath To Treat Hypoparathyroidism (RTTNews)
12.08.24	Ascendis Pharma Announces FDA Approval Of YORVIPATH - Quick Facts (RTTNews)
29.07.24	Biotech Stocks Facing FDA Decision In August 2024 (RTTNews)
05.07.24	Pendopharm Reaches Distribution Agreement With Ascendis For TransCon Parathyroid Hormone In Canada (RTTNews)
30.04.24	Biotech Stocks Facing FDA Decision In May 2024 (RTTNews)
24.04.24	Ascendis Pharma Says UK Approves YORVIPATH For Treatment Of Adults With Chronic Hypoparathyroidism (RTTNews)
05.02.24	Biotech High-Flyers That Just Hit 52-Week Highs (RTTNews)
08.01.24	Specialised Therapeutics Signs Deal With Ascendis For Commercialization Of 3 Endocrinology Therapies (RTTNews)
11.12.23	Ascendis Pharma Says FDA Accepts Resubmitted NDA For TransCon PTH In Adults With Hypoparathyroidism (RTTNews)
16.10.23	ASCENDANT ANNOUNCES APPOINTMENT OF MR. VAL COETZEE AS DIRECTOR OF PROCESS ENGINEERING (PR Newswire)
05.09.23	ASCENDANT RESOURCES ENTERS TENDER PHASE FOR MANDATED LEAD ARRANGER FOR ITS EXPORT CREDIT AGENCY SUPPORTED PROJECT FINANCING AT ITS LAGOA SALGADA PROJECT IN PORTUGAL (PR Newswire)
23.08.23	Ascendant Resources Announces Results of Annual and Special Meeting of Shareholders (PR Newswire)
01.08.23	ASCENDANT RESOURCES EARNS 80% INTEREST IN THE LAGOA SALGADA PROJECT IN PORTUGAL AND FILES FEASIBILITY STUDY (PR Newswire)
26.07.23	ASCENDANT RESOURCES ANNOUNCES POST-TAX NPV8 OF US$147 MILLION AND 39% IRR FROM INITIAL FEASIBILITY STUDY AT ITS LAGOA SALGADA PROJECT IN PORTUGAL (PR Newswire)
17.07.23	ASCENDANT RESOURCES ANNOUNCES DATE OF ANNUAL SHAREHOLDERS' MEETING (PR Newswire)
05.07.23	ASCENDANT ANNOUNCES POTENTIAL EXPORT CREDIT AGENCY SUPPORT FOR PROJECT FINANCE AT ITS LAGOA SALGADA PROJECT IN PORTUGAL (PR Newswire)
23.06.23	ASCENDANT PROVIDES UPDATE FOR ITS LAGOA SALGADA PROJECT IN PORTUGAL (PR Newswire)
02.05.23	ASCENDANT RESOURCES CONFIRMS SALEABLE GRADE CONCENTRATES ACHIEVED FOR COPPER, LEAD AND ZINC WITH STRONG RECOVERIES AND PRECIOUS METAL CREDITS AT ITS LAGOA SALGADA VMS PROJECT, PORTUGAL (PR Newswire)
01.05.23	Ascendis Pharma: FDA Issues CRL For TransCon PTH New Drug Application (RTTNews)
17.04.23	ASCENDANT PROVIDES AN UPDATE FOR ITS LAGOA SALGADA POLYMETALLIC PROJECT IN PORTUGAL (PR Newswire)
16.04.23	ROSEN, A TOP RANKED LAW FIRM, Encourages Ascendis Pharma Investors to Inquire About Securities Class Action Investigation - ASND (PR Newswire)
11.04.23	ASND EQUITY NOTICE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Ascendis Pharma Investors to Inquire About Securities Class Action Investigation - ASND (PR Newswire)
31.03.23	Biotech Stocks Facing FDA Decision In April 2023 (RTTNews)
03.11.22	Will Ascendis End The Year On A High Note? (RTTNews)
26.08.21	Ascendis Pharma Q2 Loss Widens; FDA Approves Skytrofa To Treat Pediatric Growth Hormone Deficiency (RTTNews)
08.07.21	Argus Research Initiates Equity Report Coverage on Ascendant Resources Inc. (TSX: ASND) (PR Newswire)
09.01.21	Ascendis Pharma Invests $12.5 Mln In VISEN Pharma (RTTNews)
09.03.20	What's The Path Forward For Ascendis Pharma (ASND)? (RTTNews)
27.12.19	Ascendis Pharma (ASND) Keeps Growing... (RTTNews)
29.08.19	ASND On Track, EDAP On Strong Footing, Kyowa Kirin Gets It Right The Second Time (RTTNews)
16.04.19	AXSM Has Had An Awesome Run. What Awaits These 13 Biotech Stocks In Q2, 2019? (RTTNews)
12.03.19	Ascendis Pharma - It's Been All About Growth... (RTTNews)
05.03.19	5 Top Gainers In Healthcare Sector (ASND, NITE, TCON…) (RTTNews)
04.03.19	5 Biotechs Awaiting Phase III Trial Data In March (RTTNews)
07.06.18	IMGN Prices Upsized Offering, STRM Rises On Q1 Results, PTI Tanks After-Hours (RTTNews)
15.02.18	WVE Makes A Splash, Mark Your Calendar For ANAB, For Now All's Well With DBVT (RTTNews)
31.01.18	Nitrex choisi Projexia et SAP pour le déploiement de son nouveau système ERP (PR Newswire)
26.01.18	Home Design Shines as Method Launches Urban Metallics Limited Edition Collection (PR Newswire)
10.01.18	PTIE Skyrockets On Remoxy Data, ASND On An Ascent, There Is HOPE For GBT (RTTNews)
04.01.18	APHB Is A Good Shot, ASND Keeps Inching Along, SKLN Soars, INSM To File ALIS NDA (RTTNews)
30.11.17	Manulife Leading Five Pilot Programs for New Treatments (PR Newswire)
22.11.17	À l'ouest, tout est beau : deux provinces en tête de la croissance en 2017 et 2018 (PR Newswire)
16.10.17	Ascendant Resources Inc. Opens the Market (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Zurich Insur Gr	547.60	3.13 %	K V
Logitech Intl	70.26	2.57 %	K V
Givaudan	3’919.00	1.45 %	K V
ABB	49.58	1.08 %	K V
Swiss Re	127.20	0.99 %	K V
Holcim	89.86	-0.24 %	K V
Sika	229.00	-0.35 %	K V
Swisscom	505.50	-0.49 %	K V
Nestle	75.96	-0.73 %	K V
CieFinRichemont	117.65	-0.80 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Ascendis Pharma (spons. ADRs)

Aktien Top/Flop

Meistgelesene Nachrichten